UNSPSC 51263602: Doxazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW1291F1W8, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin but generally known as doxazosin, which bears US NIH Compound Identifier 3157. European Medicines Agency schedules Doxazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06384MIG.

UNSPSC 51263602 Doxazosin is a Commodity code that nominally identifies a specific antihypertensive pharmaceutical, but recent state and local procurement activity under this code shows minimal alignment with that product scope. The single concrete opportunity on record—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—involves emergency-response pharmaceuticals and harm-reduction equipment entirely outside doxazosin's therapeutic category. A second posting, Texas Health and Human Services Commission RFI HHS0017013 on Direct-to-Manufacturer Prescriptions, is exploratory market intelligence soliciting vendor capabilities for pharmacy benefit program design rather than procurement of a specific drug product. The code shows no issuing-body pattern or repeat buyers; neither opportunity targets doxazosin specifically, and both appear to be misattributed to this code in state and local procurement systems.

Geographic activity is limited to Florida and Texas based on recent postings. The Seminole County Naloxone solicitation (IFB posted June 30, 2026, due July 26, 2023) sought 1,900 units annually with quarterly deliveries and a two-year initial term plus one-year renewal option; the Texas HHS RFI (posted April 3, 2026, response due same day) was a preliminary information-gathering mechanism with no award or budget specified. Neither solicitation addresses doxazosin procurement. This code warrants review by your procurement-taxonomy team; the recent opportunities suggest either systematic miscoding in state and local systems or genuine but narrow pharmaceutical-supply activity disconnected from the code's nominal product definition. For business development purposes, this code shows little actionable opportunity aligned to doxazosin itself.